Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00840463
Recruitment Status : Terminated (Poor enrolment)
First Posted : February 10, 2009
Last Update Posted : June 12, 2015
Gilead Sciences
Information provided by (Responsible Party):
Kelly M Chin, University of Texas Southwestern Medical Center

Brief Summary:
This is a randomized study of ambrisentan that will last 16 weeks. The study will include patients with diastolic heart failure and pulmonary hypertension. Patients will be randomized (1:1) to ambrisentan or placebo. The ambrisentan or matching placebo will be started at 2.5 mg by mouth daily and increased to 5mg and then 10mg daily, if tolerated. Patients will be seen at least monthly for 16 weeks. Adverse reactions will be reviewed and the required monthly laboratory tests (liver function testing and pregnancy testing, if applicable), will be performed. Patients will also complete an exercise test (six minute walk distance) and a quality of life survey at the baseline, week 4 and week 16 visit. An echocardiogram and a right heart catheterization and left ventricular end diastolic pressure measurement will be performed at the 16 week visit. The primary end-point is safety, and secondary end-points include the catheterization results, echocardiogram results, the walk distance and the quality of life survey. The expected completion of the study is 18 months from initiation. Ambrisentan is an FDA approved drug for PAH, but not for CHF.

Condition or disease Intervention/treatment Phase
Pulmonary Hypertension Heart Failure With Preserved Ejection Fraction Drug: Ambrisentan Other: Placebo Phase 4

Detailed Description:

Hypothesis: patients with pulmonary hypertension secondary to diastolic congestive heart failure (CHF) treated with ambrisentan for 16 weeks will have improved hemodynamics, increased exercise capacity and improved functional class with an acceptable safety profile, compared with placebo treated patients.

Objectives: to evaluate the safety and efficacy of ambrisentan treatment in patients with pulmonary hypertension due to diastolic CHF. Efficacy will be assessed by improvement in hemodynamics (PVR(Pulmonary Vascular Resistance): primary efficacy endpoint), six minute walk distance (6MWD), World Health Organization (WHO) functional class and quality of life after 16 weeks of treatment with ambrisentan. Safety of ambrisentan will be compared to placebo.

Concomitant Medication: Treatment with standard medications for CHF including diuretics and optimal blood pressure control with antihypertensive medications will be allowed throughout the study period. Diuretics adjustment will also be allowed and encouraged based on the planned diuretic management protocol. Approved medications for CHF in general are allowed as well, though it should be noted that there are no medications shown to have benefit in diastolic CHF. Patients may not be on an endothelin antagonist or sildenafil.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Diagnostic
Official Title: Safety and Efficacy Trial Using Ambrisentan for Pulmonary Hypertension Associated With Congestive Heart Failure With Preserved Left Ventricular Ejection Fraction
Study Start Date : January 2009
Actual Primary Completion Date : September 2013
Actual Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Ambrisentan

Arm Intervention/treatment
Active Comparator: 1 Drug: Ambrisentan
Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
Other Name: Letairis

Placebo Comparator: 2 Other: Placebo
Sugar pill
Other Name: The placebo will look identical to the Ambrisentan tablets

Primary Outcome Measures :
  1. The primary outcome will be a safety evaluation. The primary efficacy outcome will be Pulmonary Vascular Resistance. [ Time Frame: Four months ]

Secondary Outcome Measures :
  1. The secondary endpoints will be 6 MWD, WHO functional class, and SF-36 quality of life assessment. [ Time Frame: Four months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Catheterization

    1. Elevated pulmonary arterial pressure (PA mean >25mmHg)
    2. Elevated pulmonary vascular resistance (>240 or transpulmonary gradient (>12 mmHg)
    3. Elevated LVEDP (>15mmHg, but ≤23 mmHg)
  2. Evidence of left ventricular diastolic dysfunction: LA>4.0, LVH or diastolic dysfunction by mitral filling pattern
  3. Echocardiogram: Normal or mildly reduced LV ejection fraction (greater than or equal to 40%)
  4. Symptomatic chronic HF (WHO functional class II-IV)
  5. Baseline walk distance 100 to 400 meters
  6. Age 18 - 80 (increased from 70)

Maximal treatment of diastolic dysfunction as noted by the treating physicians with no change in medical therapy for one month prior to entry

Exclusion Criteria:

  1. Use of endothelin receptor antagonist, prostacyclin or PDE-5 inhibitor within 4 weeks of enrollment
  2. Exercise capacity limited by other illness (other lung disease, arthritis, mobility limitations)
  3. Uncontrolled systemic hypertension
  4. Uncontrolled atrial fibrillation
  5. Severe valvular disease
  6. Pregnant females- females of child bearing potential will need to use contraceptive agent barrier given the teratogenicity associated with ERA's
  7. Uncontrolled OSA

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00840463

United States, Texas
UT Southwestern Medical Center
Dallas, Texas, United States, 75390-8550
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Gilead Sciences
Principal Investigator: Kelly M Chin, MD UT Southwestern Medical Center
Principal Investigator: Fernando Torres, MD UT Southwestern Medical Center

Responsible Party: Kelly M Chin, Assistant Professor, University of Texas Southwestern Medical Center Identifier: NCT00840463     History of Changes
Other Study ID Numbers: IN-US-300-0126
First Posted: February 10, 2009    Key Record Dates
Last Update Posted: June 12, 2015
Last Verified: June 2015

Keywords provided by Kelly M Chin, University of Texas Southwestern Medical Center:
Pulmonary Hypertension
Diastolic Heart Failure

Additional relevant MeSH terms:
Heart Failure
Hypertension, Pulmonary
Heart Failure, Diastolic
Vascular Diseases
Cardiovascular Diseases
Heart Diseases
Lung Diseases
Respiratory Tract Diseases
Antihypertensive Agents